Loading…
Hosted by Unknown Host · 🇺🇸 US · EN
Established thought leaders with verified media credentials.
OncoTalks is the podcast for community oncology providers and clinicians who want to stay on top of new treatments and the latest advancements in oncology. Join Ontada Learn and community oncologists from The US Oncology Network as they explore oncology with a focus on the latest breakthroughs in cancer care. Expect concise, impactful discussions with practical clinical insights tailored for the real-world community oncology setting. Additionally, don’t miss OncoTalks Case Journeys , where experts deep dive into oncology patient cases and treatment journeys. Join as they conduct comprehensive case reviews, explore key learnings, and discuss the latest research and advances related to each case. Tune into OncoTalks and start unlocking pathways to better patient care today!
Unknown Host hosts OncoTalks | Oncology Insights at Your Fingertips.
Dr. Edward Pearson reviews pivotal clinical trial data supporting anti-CD38-based regimens and explores how clinicians can balance efficacy, tolerability, and quality of life when managing high-risk and transplant-inelig
Dr. Edward Pearson discusses the growing role of anti-CD38-based quadruplet therapy and key considerations influencing frontline therapy selection for patients with newly diagnosed, transplant-ineligible multiple myeloma
This learning module provides a brief overview of HER2 testing in metastatic non-small cell lung, bladder, rectal, cervical, biliary tract, ovarian, pancreatic, endometrial, and colon cancers, highlighting disease-specif
In this episode of OncoTalks, Dr. Yair Levy shares his approach to BTKi selection for patients with chronic lymphocytic leukemia (CLL), highlighting the growing role of second-generation BTK inhibitors, and the importanc
In this episode of OncoTalks, host Tulsi Patel is joined by Dr. Yair Levy to discuss the growing impact of utilization management policies on chronic lymphocytic leukemia (CLL) care. As treatment options expand, personal
Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispec
With limited durable options available, new approaches are urgently needed in EP-NEC. This episode highlights emerging therapies, including immunotherapy‑based strategies and early clinical trial data shaping future trea
Explore the current EP‑NEC treatment landscape, from first‑line platinum‑based therapy and etoposide to second‑line challenges. Dr. Pelster reviews guideline‑recommended options, sequencing considerations, and why clinic
Dr. Meredith Pelster introduces extrapulmonary neuroendocrine carcinoma (EP‑NEC), outlining how patients present and what distinguishes this rare disease. Learn the key elements of diagnostic workup, including pathology,
In this episode of OncoTalks, host Tulsi Patel speaks with Brandon Dyson, PharmD, BCOP, BCPS, Director of Pharmacy Education at Texas Oncology, about how the Maximum Fair Price (MFP) program may influence prostate cancer
In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only ap
In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing
In the final episode of this four-part series, Dr. Mohit Narang looks ahead to emerging innovations in multiple myeloma. Learn about new therapeutic targets, MRD testing, sequencing strategies, and personalized approache
In part three of four, Dr. Mohit Narang explores how bispecific antibodies and other advanced treatments are being implemented in real-world community oncology practices. Discover the operational challenges, safety consi
In part two of four, Dr. Mohit Narang examines the rapidly evolving treatment landscape for multiple myeloma. Tune in to learn how therapy has progressed from doublets to quadruplets, reshaping the role of autologous ste
In part one of four, Dr. Mohit Narang from Maryland Oncology Hematology provides a foundational overview of multiple myeloma. Tune in to learn how its incidence has evolved over the past thirty years, what we know today
In this OncoTalks Case Journey, Dr. Paul Conkling discusses the importance of comprehensive genomic profiling and targeted therapy in non-small cell lung cancer (NSCLC). Through the lens of two NSCLC patients who receive
Live from McKesson Accelerate 2025, Dr. Ira Zackon sits down with Dr. Martin Dietrich to discuss the latest in ROS1+ non-small cell lung cancer. They explore the rarity and significance of ROS1 mutations and clinical pre
Live from McKesson Accelerate 2025, host Suzzette Arnal talks with Dr. Melissa Johnson about how precision medicine is reshaping care for non-small cell lung cancer patients. They cover comprehensive biomarker testing, t
In this episode of OncoTalks, Dr. Paul Conkling and Dr. Eric Nadler take a deep dive into the IMforte trial—a pivotal phase III global study evaluating lurbinectedin and atezolizumab as a first-line maintenance therapy f
Melissa Johnson
The Accidental Entrepreneur: Finding Leadership and Joy through Cupcakes · American Red Cross Military and Veteran Caregiver Network
1 appearance on this show
Brandon Dyson
Texas Oncology
1 appearance on this show
Dr. Mohit Narang
Maryland Oncology Hematology
1 appearance on this show
Dr. Martin Dietrich
unclear
1 appearance on this show
Dr. Ira Zackon
Ontada
1 appearance on this show
Dr. Marcus Neubauer
The US Oncology Network
1 appearance on this show
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch OncoTalks | Oncology Insights at Your Fingertips, visit https://feed.podbean.com/oncotalks/feed.xml for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent education coverage.
OncoTalks | Oncology Insights at Your Fingertips is hosted by Unknown Host. The show is categorised under Education (health) and has published 0 episodes.
OncoTalks | Oncology Insights at Your Fingertips regularly covers Education, Health, Fitness, Medicine. It sits in the Education category, with a health focus.
OncoTalks | Oncology Insights at Your Fingertips is accessible for guests with genuine education expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
OncoTalks | Oncology Insights at Your Fingertips hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of OncoTalks | Oncology Insights at Your Fingertips average 8 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates OncoTalks | Oncology Insights at Your Fingertips's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 2 days ago.